OXiGENE to Present at 12th Annual BIO Investor Forum Conference on October 8,
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, announced that Peter Langecker, M.D., Ph.D.,
President and Chief Executive Officer, will provide a corporate overview at
the 12^th Annual BIO Investor Forum conference on October 8, 2013 at 4:00 PT
at the Palace Hotel, San Francisco, California.
To access the live audio webcast of the presentation, please log on through a
link located in the Investors section of OXiGENE's website at www.oxigene.com,
under the Events and Presentations tab. A replay of the webcast will be
available one hour after the conclusion of the live event.
OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents (VDAs) that selectively disrupt abnormal blood vessels
associated with solid tumor progression. OXiGENE is dedicated to leveraging
its intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact:
Press spacebar to pause and continue. Press esc to stop.